Hypha LabsFUNI +15.38% 3-Year ROIIC % is 133.65 as of Sep. 2025, which is 208% above its 10-year median of 43.40. The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Hypha Labs ranks better than 83.74% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Hypha Labs's 3-Year ROIIC % for the quarter that ended in Sep. 2025 was 133.65%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Hypha Labs's 3-Year ROIIC % or its related term are showing as below:
FUNI's 3-Year ROIIC % is ranked better than 83.74% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs FUNI: 133.65
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Hypha Labs 3-Year ROIIC % Related Terms
Hypha Labs 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Hypha Labs's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FUNI vs IVRO, PRPH, IDTA: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Hypha Labs's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypha Labs 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Hypha Labs's 3-Year ROIIC % falls into.
Hypha Labs's 3-Year ROIIC % for the quarter that ended in Sep. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.001 (Sep. 2025) - -1.15 (Sep. 2022) )
/
( 1.734 (Sep. 2025) - 3.119 (Sep. 2022) )
=
-1.851
/
-1.385
=
133.65%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Hypha Labs (FUNI) has a 3-Year ROIIC % of 133.65 as of Sep. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hypha Labs and its competitors. This is 208% above median its historical median of 43.40. According to the industry distribution chart, Hypha Labs ranks #33 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 16.3%.
Is Hypha Labs' 3-Year ROIIC % too high?
Hypha Labs' current 3-Year ROIIC % of 133.65 is 208% above median its 10-year median of 43.40. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.22. Hypha Labs' value of 133.65 is 60650% above this industry median. Based on the distribution chart, Hypha Labs ranks #33 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Hypha Labs' 3-Year ROIIC % compare to IVRO and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Hypha Labs ranks #33 out of 203 companies for 3-Year ROIIC %. This places Hypha Labs in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.22. Hypha Labs' value of 133.65 is 60650% above this benchmark. While the company's 10-year median is 43.40 vs. the industry median of 0.22, Hypha Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hypha Labs's current 3-Year ROIIC % of 133.65 is 60650% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Hypha Labs and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypha Labs's current 3-Year ROIIC % is 133.65, which is 208% above median its own 10-year median of 43.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypha Labs stock overvalued right now?
Hypha Labs (FUNI) has a current 3-Year ROIIC % of 133.65. The current 3-Year ROIIC % is 133.65, which is 208% above median its 10-year median of 43.40 and 60650% above the Medical Diagnostics & Research industry median of 0.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Hypha Labs (FUNI), the current 3-Year ROIIC % is 133.65 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hypha Labs Inc engaged in the research, development, and commercialization of the Hypha Micropearl accelerator, an in-home, web-based, computer-controlled bioreactor designed to accelerate the production of nutritionally beneficial mushrooms for human consumption. The Company's easy-to-use device, together with replaceable cartridges ordered through its exclusive app, safely and effectively produced enriched mycelium of functional mushrooms, or Micropearls, in eight days. These Micropearls contained active mushroom ingredients in a concentrated, easy-to-handle, tasteless, and odorless form that could be incorporated into various foods and beverages without altering flavor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FUNI has been successfully added to your 